Careers

Passionate to help us save lives?

The war in Ukraine also shocks Biotest AG.

"We are deeply shocked that a war has broken out in the middle of Europe. This war affects people on both sides of the border, where sons and daughters are committed to a war that only brings suffering and pain. War can never be accepted as a means of resolving conflicts," says Dr. Michael Ramroth, CEO of Biotest AG. "We stand behind the Ukrainian people and condemn the invasion of Russian troops into the country.”

Biotest donates blood coagulation drug worth 290,000 euros for young Ukrainian refugees

In cooperation with the Deutsche Bluthilfe e.V., Biotest has supplied young haemophilia patients from Ukraine who have fled the war with the blood coagulation drug Haemoctin.

Biotest donates for young Ukrainian refugees
PDF, 331 KB
[ Download ]

500,000 Euros: Biotest makes another donation for blood coagulation drugs Haemoctin® and Haemonine® for young Ukrainian refugees

Biotest has once again donated its Factor VIII and Factor IX preparations to Deutsche Bluthilfe e. V., based in Duisburg, Germany, to ease at least one worry for those affected by congenital blood coagulation disorders and their families. 
Patients with hemophilia A ("bleeding disorder") have a congenital deficiency of clotting factor VIII (factor 8) and are constantly at risk of internal bleeding. They therefore need a coagulation factor drug at regular intervals to compensate for the lack of the vital blood protein.

 

Admission of all offer conditions

Grifols S.A. will acquire majority of voting rights in Biotest AG

Activities of Biotest Group against the coronavirus

TV reports, press releases and the presentation of Biotest's research activities.

The fight against COVID-19 begins with you.

You have recovered. Then you can save others.

We are developing a potential drug. First, we need your plasma.

Be part of this historic initiative to fight the coronavirus pandemic.

A global industry addresses global challenges related to covid-19: A PPTA initiative

Leaders of the plasma-processing industry express their appreciation and gratitude for plasma donors and their commitment to providing lifesaving plasma for patients around the world.
An initiative of  the Plasma Protein Therapeutics Association.

Intensive care medicine

Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.

Haematology

For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.

Clinical immunology

Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).

Human Albumin for manufacturing and research use

Through its wide range of biological functions, its stability and high solubility, Biotest Human Serum Albumin is suitable for use as a multifunctional excipient for biotechnological,  pharmaceutical and diagnostic applications. It is manufactured in a GMP compliant, state-of-the-art facility and complies with the regulatory requirements of multiple health authorities.

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.